Optimas Capital’s West Pharmaceutical WST Stock Holding History

Optimas Capital’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,800	Closed	-$2.93M	–	57
2023 Q3	$2.93M	Buy	+7,800	New	+$3.02M	2.01%	14

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Optimas Capital's WST Position: Q4 2023 in Review

Optimas Capital sold out of West Pharmaceutical (WST) in Q4 2023, closing a stake of 7,800 shares — an estimated $2.93M sold.

Optimas Capital first reported a position in WST in Q3 2023 and held it in 1 quarter. The position peaked at $2.93M in Q3 2023. 782 funds tracked by Wall St. Rank hold WST as of Q4 2023.

Optimas Capital reported no remaining West Pharmaceutical position as of Q4 2023 after selling out during the quarter.
Optimas Capital sold 7,800 West Pharmaceutical shares in Q4 2023, an estimated $2.93M.
Optimas Capital first reported a position in West Pharmaceutical in Q3 2023 and held it in 1 quarter.
Optimas Capital's West Pharmaceutical position peaked at $2.93M in Q3 2023.
782 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2023.

Based on Optimas Capital's 13F filing for Q4 2023, filed 23 Jan 2024.